Protagonist Therapeutics, Inc.
PTGX
Rank in Stocks
#2275
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Share Price
$137.92
Market Cap
$8.92B
Change (1 day)
2.59%
Change (1 year)
79.77%
Country
US
Trade Protagonist Therapeutics, Inc. (PTGX)
Category
Healthcare
Stock split history for Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. stock (symbol: PTGX) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One PTGX share bought prior to Oct 20, 2026 would equal to 0 PTGX shares today.
The most recent stock split occurred on Oct 20, 2026.
One PTGX share bought prior to Oct 20, 2026 would equal to 0 PTGX shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
